CellMax, a leading cancer diagnostics company, based in California, has reportedly announced that it has partnered with Medigen Biotech, in a bid to provide the latter with the CMxTM (its circulating tumor cell platform). Sources claim that Cellmax, through this partnership, aims to help Medigen assess the selection and response for cancer cell therapy treatment.
The multi-center, single arm, open-label clinical trial will apparently be enrolling patients suffering from Stage II and III colorectal cancer which has been surgically resected, or perhaps surgically resected and then treated with chemotherapy. The phase I trial will commence in 2019, and patients testing positive on the CellMax Life blood test will be receiving the NK cell therapy.
Dr. Stanley Chang, Chairman and CEO, Medigen Biotech, was reportedly quoted stating that they needed a non-invasive blood test that can not only be utilized to screen for the initial treatment selection, but can also be used myriad times to monitor patients. Dr. Chang added that test sensitivity is the important criteria for platform selection, as they expect to take patients having early stage cancer.
Atul Sharan, Co- Founder and CEO, CellMax Life, was reportedly quoted stating that the second deadliest cancer in the U.S. is colorectal cancer, with 1,50,000 new cases and $14 billion spent on treatment annually. Medigen’s vision is to develop cancer therapies for early stage detection, quite coherently complements CellMax’s mission to lower mortality rate from colorectal cancer. He added that they are happy regarding the fact that the oncoming clinical trial would bring benefits to patients suffering from colorectal cancer.
About CellMax Life
CellMax Life is a diagnostics firm, headquartered in Sunnyvale, California, focusing on cancer screening with a patented technology for detecting precancer cells and cancer cells in a single sample of blood. CellMax Life has a CLIA certified and CAP accredited laboratory at their location.
About Medigen Biotech
Medigen Biotech, a biopharmaceutical firm, primarily focused on novel cell therapy technology and new drug development for cancer treatment. The company has now advanced into a biomedical group with business fields catering to cell-based vaccine technology, molecular diagnosis, and manufacturing of biologics and ophthalmic drugs.
